# KPV

> Evidence tier C — Animal data · Repair · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/kpv/

Also known as: Lys-Pro-Val, α-MSH (11-13)

## Quick answers

**What is KPV?**

A tripeptide fragment of alpha-MSH with potent anti-inflammatory and antimicrobial activity.

**How strong is the evidence for KPV?**

Tier C (animal data) on the peptidemeta evidence scale. Only cell and animal (mainly colitis model) studies are published; no completed human trials.

**Is KPV FDA-approved?**

No. KPV is not approved by the FDA for any use.

**Is KPV banned in sport?**

Yes. KPV is prohibited in sport by the World Anti-Doping Agency under S0 (non-approved substances).

**How does KPV work?**

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH that enters cells and directly inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation. This blocks transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and reduces intestinal and systemic inflammation.

**What is known about the safety of KPV?**

Limited formal human safety data. Preclinical studies show good tolerability.

## Key facts

- **Evidence tier:** C (Animal data)
- **FDA:** not approved
- **WADA:** prohibited (S0)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular

## Overview

A tripeptide fragment of alpha-MSH with potent anti-inflammatory and antimicrobial activity. It modulates NF-kB signaling and is explored for gut and skin inflammation.

## Mechanism

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH that enters cells and directly inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation. This blocks transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and reduces intestinal and systemic inflammation.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Reduced intestinal inflammation
- Modulated immune response via NF-kB inhibition
- Antimicrobial activity against pathogens
- Improved skin inflammatory conditions

## Safety & unknowns

Limited formal human safety data. Preclinical studies show good tolerability. As a fragment of endogenous alpha-MSH, it is expected to have a favorable safety profile. Not FDA-approved.

## Status sources

- [PubMed: KPV tripeptide](https://pubmed.ncbi.nlm.nih.gov/?term=KPV+tripeptide)
- [WADA 2026 Prohibited List](https://www.wada-ama.org/en/prohibited-list)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.